All Q2 FY26 results →

I.

Illumina, Inc.

Q2 FY26Life Sciences Tools and Services

Illumina, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹159

Market cap₹24.0K Cr

P/E26.4

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

3 of 4 strong

RevenueModerate growth

MarginMargins up

CapexCapex planned

Order bookOrder book rising

The short version

- Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical market, with potential upside beyond current guidance. - Illumina expects continued revenue growth with an updated 2026 revenue guidance raised to $4.52 billion to $4.62 billion, reflecting Q1 outperformance.

From Illumina, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth

Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical market, with potential upside beyond current guidance.
Research and applied markets are expected to remain cautious, with mid- to high single-digit declines anticipated for the year, though some improvement is possible later in 2026.
NovaSeq X instrument placements remain strong, with demand outpacing supply; over 85% of clinical customer transition to NovaSeq X is expected by year-end 2026.
Total sequencing gigabase output grew over 30% year-over-year, driven mainly by clinical growth well above that.
Revenue guidance for 2026 was raised to $4.52 billion to $4.62 billion, with Rest of World organic growth expected at 2-4%, clinical consumables growth in low double digits to mid-teens, and research consumables down mid- to high single digits.

2 more points from Illumina, Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

Illumina expects continued revenue growth with an updated 2026 revenue guidance raised to $4.52 billion to $4.62 billion, reflecting Q1 outperformance.
Operating margins are forecasted to expand by approximately 140 basis points year-over-year in 2026, targeting 23.4% to 23.6%, up 10 basis points from prior guidance.
Non-GAAP EPS guidance for 2026 is increased to a range of $5.15 to $5.30, representing about 12% growth at the midpoint excluding acquisitions.
They anticipate mid-single-digit organic growth in 2026 with a focus on mid-teens growth in the clinical market segment.
Operating margin improvements are expected despite short-term inflationary pressures, with mitigating actions to offset these effects fully.

2 more points from Illumina, Inc.'s call on margins

Create a free account to keep reading this call

See what Illumina, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

In Q1 2026, Illumina's capital expenditures were $38 million.
The company is scaling up BioInsight, which may involve strategic investments; timing of partnerships and data deals can be lumpy.
Operational focus includes investment to scale supply, noted as a headwind in Q2 with effects visible in Q3 and Q4.
Illumina closed the acquisition of SomaLogic on January 30, 2026, with a net cash payment of $363 million plus potential royalties and milestone payments.
Subsequent to quarter-end, Illumina paid the first milestone of $25 million related to SomaLogic's 2025 targets.

2 more points from Illumina, Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

In Q1, Illumina repurchased 2 million shares for approximately $242 million, indicating active capital deployment.
At quarter end, approximately $400 million remained on the current share repurchase authorization.
The Board authorized an additional $1.5 billion in share repurchases, showing a commitment to returning capital to shareholders.
Illumina ended Q1 with approximately $1.16 billion in cash, cash equivalents, and short-term investments.

2 more points from Illumina, Inc.'s call on fundraising

Create a free account to keep reading this call

See what Illumina, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising

Illumina is experiencing very strong demand and a robust pipeline for both instruments and consumables.
Year-over-year, performance obligations (indicating backlog) are up more than 20%.
Supply constraints exist but the company is scaling up production to meet demand.
Q2 placements are expected to be close to Q1 levels (~80 NovaSeq X units).

2 more points from Illumina, Inc.'s call on order book

Create a free account to keep reading this call

Others in Life Sciences Tools and Services this season

Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
West Pharmaceutical Services, Inc. (Q2 FY26)
West Pharmaceutical Services, Inc. Q2 FY26 quarterly results analysis. Revenue growth guidance for 2026 increased to 7% to 9% organic growth, reflecting strong

Compare:vs Danaher Corporation vs Waters Corporation vs IQVIA Holdings Inc.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Illumina, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Illumina, Inc. Q2 FY26 results?

- Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical market, with potential upside beyond current guidance. - Illumina expects continued revenue growth with an updated 2026 revenue guidance raised to $4.52 billion to $4.62 billion, reflecting Q1 outperformance.

What is Illumina, Inc. share price analysis?

Illumina, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 26.4 with a market cap of $24,011. Investors should review the full earnings analysis for detailed insights.

Is Illumina, Inc. planning capital expenditure?

- In Q1 2026, Illumina's capital expenditures were $38 million.

Keep Illumina, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.